热疗联合AP方案及恩度治疗晚期非小细胞肺癌临床研究  

Clinical Study on Thermotherapy Combined with AP Scheme and Endostar for Advanced Non-Small Cell Lung Cancer

作　　者：任婧[1] 杨瑞娜[1] 袁小志[1] 孔国强[1] REN Jing;YANG Ruina;YUAN Xiaozhi;KONG Guoqiang

机构地区：[1]河南科技大学第一附属医院肿瘤内科,河南洛阳471003

出　　处：《新中医》2022年第20期137-142,共6页New Chinese Medicine

摘　　要：目的:研究热疗联合AP方案(培美曲塞联合卡铂)及恩度治疗晚期非小细胞肺癌(NSCLC)的临床疗效,以及其对患者血清肿瘤标志物、血管内皮生长因子(VEGF)、碱性成纤维细胞生长因子(bFGF)、血小板衍生生长因子(PDGF)水平和生活质量的影响。方法:选择290例晚期NSCLC患者作为研究对象,按随机数字表法分成2组各145例。对照组给予AP方案联合恩度治疗,观察组在此基础上加用热疗治疗。连续治疗4个周期后观察2组近期疗效。治疗前后检测2组血清肿瘤标志物[癌胚抗原(CEA)、糖类抗原125(CA125)、细胞角蛋白19片段抗原21-1(CYFRA21-1)、鳞状上皮细胞癌抗原(SCC-Ag)]及血管生成相关因子(VEGF、bFGF、PDGF)水平,并使用癌症治疗功能评价系统-肺癌模块(FACT-L)评价患者的生活质量。记录并比较2组毒副反应情况。结果:客观有效率观察组57.93%(84/145),对照组41.38%(60/145),2组比较,差异有统计学意义(P<0.05)。治疗后,2组血清CEA、CA125、CYFRA21-1、SCC-Ag水平均较治疗前降低,差异均有统计学意义(P<0.05),且观察组明显低于对照组,差异均有统计学意义(P<0.05)。治疗后,2组血清VEGF、bFGF和PDGF水平均较治疗前下降,差异均有统计学意义(P<0.05);且观察组血清VEGF、bFGF及PDGF浓度均低于对照组,差异均有统计学意义(P<0.05)。治疗后,观察组FACT-L中生理状态、情感状态、活动能力、附加关注情况评分均较治疗前增高,差异均有统计学意义(P<0.05);对照组FACT-L各维度评分治疗前后比较,差异均无统计学意义(P>0.05),2组间FACT-L各维度除社会/家庭状况评分外比较,差异均有统计学意义(P<0.05)。2组各项毒副反应(包括胃肠道反应、骨髓抑制、周围神经毒性等)发生率比较,差异均无统计学意义(P>0.05)。结论:热疗联合AP方案及恩度治疗晚期NSCLC能有效抑制患者血清肿瘤标志物与促血管生成相关因子的表达水平,提高患者生活质量,近期Objective:To study the clinical effect of thermotherapy combined with AP scheme(pemetrexed and carboplatin)and Endostar for advanced non-small cell lung cancer(NSCLC),and its effect on levels of tumor markers in serum,vascular endothelial growth factor(VEGF),basic fibroblast growth factor(bFGF)and platelet-derived growth factor(PDGF)as well as quality of life.Methods:A total of290 cases of patients with advanced NSCLC were selected as the study subjects and divided into two groups according to the random number table method,with 145 cases in each group.The control group was treated with AP scheme combined with Endostar,and the observation group was additionally treated with thermotherapy based on the treatment of the control group.After four courses of treatment,the short-term curative effect in the two groups were observed.Before and after treatment,the levels of tumor markers in serum including carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),cytokeratin 19 fragment antigen 21-1(CYFRA21-1)and squamous cell carcinoma antigen(SCC Ag),as well as levels of pro-angiogenic factors including VEGF,bFGF and PDGF in the two groups were detected,and the quality of life was evaluated by Functional Assessment of Cancer Therapy-Lung(FACT-L).The incidence of toxicity and side effects in the two groups was recorded and compared.Results:The objective effective rate was 57.93%(84/145)in the observation group and 41.38%(60/145)in the control group,the difference being significant(P<0.05).After treatment,the levels of CEA,CA125,CYFRA21-1 and SCC-Ag in serum in the two groups were decreased when compared with those before treatment,differences being significant(P<0.05),and the levels in the observation group were significantly lower than those in the control group,differences being significant(P<0.05).After treatment,the levels of VEGF,bFGF and PDGF in serum in the two groups were decreased when compared with those before treatment,differences being significant(P<0.05),and the concentration of VEGF,bFGF and PDGF in ser

关 键 词：晚期非小细胞肺癌 热疗 化疗方案 恩度 肿瘤标志物 促血管生成因子 生活质量 

分 类 号：R734.2[医药卫生—肿瘤]